RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2016 /PRNewswire/ -- Marken announced today that their Moscow depot was granted a new pharmaceutical license from the Russian Federation.
In addition to the storage and transportation of drugs used in clinical trials as a service offered by all of Marken's depots, Marken's newest Moscow Depot will now be legally authorized to perform the following activities:
- Wholesale trade of drug substances for medicinal application, including patented drugs
- Comparator drugs sourcing from Russian market
- Expiry date relabeling for investigational medicinal products only
- Label application for Clinical Trials Only
- Controlled (IV-V) schedules (RU), handling, and distribution of cytotoxic & highly potent substances, within frames of clinical trials
The head of local operations in Moscow and Technical Director, Anastacia Kurianova, credited the entire Moscow team for earning the pharmaceutical license. Kurianova commented, "The license demonstrates Marken's commitment to this community and patients. We will continue to seek new and industry-specific ways to meet the growing needs of our clients in Russia."
Russia's pharmaceutical market revenues are forecasted to flourish at rates similar to other emerging markets and could total over $25 billion by 2018i. Marken, as the first life science supply chain organization to establish a depot in Moscow, recognizes Russia's significant contributions to the pharmaceutical market in Central and Eastern Europe.
Wes Wheeler, Marken's Chief Executive Officer, emphasized that, "With over 400 pharmaceutical companies, Russia is on track to develop dynamically in the life sciences industry when compared to other European markets. Our team in Moscow makes it a priority to consistently exceed clinical supply chain expectations and capabilities."
In December 2015, Marken announced the grand opening of a dedicated, fully-owned depot in Moscow, Russia. To complement the organizations expanding network, the GMP Certified depot offers clinical and commercial pharmaceutical drug storage, clinical trial services and distribution. Dedicated space was built into the design for drug product storage as well as returns and destruction for rejected goods. All of the spaces and equipment are compliant with Marken's Good Manufacturing Practice specifications. The secure facility is located in a new building and is equipped to handle a full spectrum of temperature controlled packaging and shipments, plus liquid nitrogen storage capabilities. In addition to the dedicated space for drug product storage, standard services such as pick and pack, labelling and late stage customization are offered within this depot and throughout the entire Marken network.
The Moscow facility is managed by the company's global inventory system, Marken Solo™, and as with all Marken-owned depots, offers clients real time access to live data reporting on environmental conditions inside the depot. Solo connects to Marken's Maestro system which books and tracks all shipments into and out of the depot on a real time basis.
Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments, and offers a state of the art GMP-compliant depot network and logistic hubs in 43 locations worldwide. Marken's 630 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken's unique position in the pharma and logistics industry.
i IMS Health